NKT-cell-based immunotherapies in clinical trials

Clinical Immunology

Volumn 140, Issue 2, 2011, Pages 117-118

  Exley, Mark A ^a   Nakayama, Toshinori ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CD1D ANTIGEN; CELL MARKER; T LYMPHOCYTE RECEPTOR ALPHA CHAIN;

ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; CLINICAL TRIAL; EDITORIAL; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNOTHERAPY; MEDICAL LITERATURE; MELANOMA; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; SICKLE CELL ANEMIA; SICKLE CELL CRISIS; T LYMPHOCYTE; VIRUS HEPATITIS;

ANIMALS; ANTIGENS, CD1D; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; NATURAL KILLER T-CELLS; NEOPLASMS;

EID: 79960468556     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2011.04.015     Document Type: Editorial

References (21)

1. Godfrey D.I., Kronenberg M. Going both ways: immune regulation via NKT cells. J. Clin. Invest. 2004, 114:1379.
2. Parekh V.V., Wilson M.T., Van Kaer L. iNKT-cell responses to glycolipids. Crit. Rev. Immunol. 2005, 25:183-213.
3. Bendelac A., Savage P.B., Teyton L. The biology of NKT cells. Annu. Rev. Immunol. 2007, 25:297-336.
4. Nowak M., Stein-Streilein J. Invariant NKT cells and tolerance. Int. Rev. Immunol. 2007, 26:95-119.
5. Matsuda J.L., Mallevaey T., Scott-Browne J., Gapin L. CD1d-restricted iNKT cells, the 'Swiss-Army knife' of the immune system. Curr. Opin. Immunol. 2008, 20:358-368.
6. Cohen N.R., Garg S., Brenner M.B. Antigen presentation by CD1 lipids, T cells, and NKT cells in microbial immunity. Adv. Immunol. 2009, 102:1-94.
7. Taniguchi M., Tashiro T., Dashtsoodol N., Hongo N., Watarai H. The specialized iNKT cell system recognizes glycolipid antigens and bridges the innate and acquired immune systems with potential applications for cancer therapy. Int. Immunol. Jan 2010, 22(1):1-6. (Epub 2009 Oct 25. PMID: 19858073).
8. Salio M., Silk J.D., Cerundolo V. Recent advances in processing and presentation of CD1 bound lipid antigens. Curr. Opin. Immunol. Feb 2010, 22(1):81-88. (Epub 2010 Jan 14. PMID: 20080041).
9. Venkataswamy M.M., Porcelli S.A. Lipid and glycolipid antigens of CD1d-restricted natural killer T cells. Semin. Immunol. Apr 2010, 22(2):68-78. (Epub 2009 Nov 27. PMID: 19945296; PMCID: PMC2837800).
10. Kohrt H.E., Pillai A.B., Lowsky R., Strober S. NKT cells, Treg, and their interactions in bone marrow transplantation. Eur. J. Immunol. Jul 2010, 40(7):1862-1869. (PMID: 20583031; PMCID: PMC2926162).
11. Godfrey D.I., MacDonald H.R., Kronenberg M., Smyth M.J., Van Kaer L. NKT cells: what's in a name?. Nat. Rev. Immunol. Mar 2004, 4(3):231-237.
12. Berzins S.P., Smyth M.J., Baxter A.G. Presumed guilty: natural killer T cell defects and human disease. Nat. Rev. Immunol. Feb 2011, 11(2):131-142.
13. Schneiders F.L., Scheper R.J., von Blomberg B.M., Woltman A.M., Janssen H.L., van den Eertwegh A.J., Verheul H.M., de Gruijl T.D., van der Vliet H.J. Clinical experience with α-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection. Clin. Immunol. 2011, 140:130-141.
14. Dhodapkar M.V., Richter J. Harnessing natural killer T (NKT) cells in human myeloma: Progress and challenges. Clin. Immunol. 2011, 140:160-166.
15. Motohashi S., Okamoto Y., Yoshino I., Nakayama T. Anti-tumor immune responses induced by iNKT cell-based immunotherapy for lung cancer and head and neck cancer. Clin. Immunol. 2011, 140:167-176.
16. Metelitsa L.S. Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans. Clin. Immunol. 2011, 140:119-129.
17. Dellabona P., Casorati G., de Lalla C., Montagna D., Locatelli F. On the use of donor-derived iNKT cells for adoptive immunotherapy to prevent leukemia recurrence in pediatric recipients of HLA haploidentical HSCT for hematological malignancies. Clin. Immunol. 2011, 140:152-159.
18. Padte N.N., Li X., Tsuji M., Vasan S. Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant. Clin. Immunol. 2011, 140:142-151.
19. Field J., Nathan D., Linden J. Targeting iNKT cells for the treatment of sickle cell disease. Clin. Immunol. 2011, 140:177-183.
20. Exley M., Lynch L., Varghese B., Nowak M., Alatrakchi N., Balk S. Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: Reversing tumor-induced defects. Clin. Immunol. 2011, 140:184-195.
21. Hogan A., O'Reilly V., Dunne M., Dere R., Zeng S., O'Brien C., Amu S., Fallon P., Exley M.A., O'Farrelly C., Zhu X., Doherty D. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide. Clin. Immunol. 2011, 140:196-207.